NOX 2.86% 7.2¢ noxopharm limited

I agree that 'breakthrough' is a premature description if the...

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    I agree that 'breakthrough' is a premature description if the reader thinks that it applies to pre-clinical drugs targeting pancreatic and gallbladder cancers.

    I respectfully suggest, however, that the breakthrough in this case refers to the ability to retard the Phase 2 metabolism process.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.